Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic CD19-specific T Cells for Refractory B-Lineage Malignancies
NCT02274506Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2014
- Primary completion
- Oct 2014
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of allogeneic CD19-specific T cells in acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), small lymphocytic lymphoma (SLL) and 3 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 12 hours. Planned start Oct 2014; status: withdrawn.
02
Drugs
allogeneic CD19-specific T cells
03
Conditions
acute lymphoblastic leukemia (ALL)diffuse large B-cell lymphoma (DLBCL)small lymphocytic lymphoma (SLL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02274506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02274506.